Mayence Annie, Vanden Eynde Jean Jacques
Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium.
Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium.
Pharmaceuticals (Basel). 2019 Mar 12;12(1):37. doi: 10.3390/ph12010037.
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.
2018年，巴瑞替尼被美国食品药品监督管理局（FDA）批准用于治疗类风湿性关节炎。巴瑞替尼通过靶向 Janus 激酶（JAK）发挥作用。在本研究中，我们描述了使用两种替代途径制备该药物的必要步骤。
